- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- 3.1 Articles of Organization
- 4.12 Form of Common Stock Purchase Warrant
- 4.13 Registration Rights Agreement
- 10.5 Lease Relating to Certain Property In Waltham, Ma
- 10.43 Amendment No. 7 to License & Option Agreement with LG Life Sciences, LTD.
- 10.44 License, Supply Marketing Agreement with Menarini Int'l Operation Luxembourg
- 12.1 Statement Re: Computation of Ratios
- 21.1 Subsidiaries of the Registrant
- 23.1 Consent of Ernst & Young LLP
- 31.1 Consent of Chief Executive Officer Pursuant to Section 302
- 31.2 Consent of Chief Financial Officer Pursuant to Section 302
- 32.1 Consent of Chief Executive Officer Pursuant to Section 906
- 32.2 Consent of Chief Financial Officer Pursuant to Section 906
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-137596, No. 333-133370, No. 333-128735, No. 333-118026, No. 333-113359, No. 333-111273, No. 333-110006 and No. 333-106602) and in the Registration Statements on Form S-8 (No. 333-138309, No. 333-116707, No. 333-112810, No. 333-106563, No. 333-97139, No. 333-58274, No. 333-39390, No. 333-30920, No. 333-92951, No. 333-49069, No. 333-30617, No. 333-15935, No. 033-61191, No. 033-75136, No. 033-45432, No. 033-27885, No. 033-12633, No. 002-95446, No. 002-81123 and No. 002-77846) of Oscient Pharmaceuticals, Corporation of our reports dated March 12, 2007, with respect to the consolidated financial statements and schedule of Oscient Pharmaceuticals Corporation, Oscient Pharmaceuticals Corporation’s management’s assessment of the effectiveness of internal control over financial reporting, and the effectiveness of internal control over financial reporting of Oscient Pharmaceuticals Corporation, included in the Annual Report (Form 10-K) for the year ended December 31, 2006.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 12, 2007